Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma

This trial is testing a drug called dinutuximab beta — an antibody that targets neuroblastoma cancer cells — combined with two different chemotherapy regimens, in children and young people with high-risk stage M neuroblastoma (a childhood cancer that starts in nerve cells) who have not yet received any treatment. **You may be eligible if...** - Your child has been diagnosed with high-risk Stage M neuroblastoma - Your child is between 18 months and 18 years old - Your child weighs more than 12 kg - Your child's liver, kidneys, and heart are functioning adequately - Your child has not yet received any cancer treatment - Parents or legal guardians have provided written informed consent **You may NOT be eligible if...** - Your child has already received cancer treatment for neuroblastoma - Your child requires certain medications prohibited by the study (e.g., corticosteroids) - Your child has significant organ dysfunction Talk to your doctor to see if this trial is right for you.